Is craf activation mutation locate in the atop binding domain?
Best insight from top research papers
The abstracts provided do not directly answer the question of whether the CRAF activation mutation is located in the ATP binding domain.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The paper does not mention anything about a "atop binding domain" or the location of the CRAF activation mutation. | |
43 Citations | The provided paper does not mention anything about a "craf activation mutation" or an "atop binding domain." |
| The provided paper does not mention anything about a "craf activation mutation" or the "atop binding domain." | |
| The paper does not mention a specific mutation in the atop binding domain of CRAF. The paper focuses on the interaction between KRAS and RAF1. | |
38 Citations | The provided paper does not mention a specific mutation in the CRAF activation domain. |
Related Questions
Is there a small molecule that activates Smad1?5 answersYes, small molecules have been identified that activate Smad1 signaling. Research efforts have led to the discovery of small molecule activators of BMP signaling, such as flavonoids, which induce luciferase activity in a dose-dependent manner and ventralize zebrafish embryos. Additionally, compounds have been found that block the WW1 domain of Smurf1, a negative regulator of the BMP pathway, from interacting with Smad1/5, thereby increasing BMP signal responsiveness. Furthermore, the activation of Smad1 signaling has been implicated in fibrosis, with studies showing that imatinib mesylate can block the Smad1 pathway in fibroblasts, indicating its potential as an antifibrotic agent. These findings collectively demonstrate the existence of small molecules that can activate Smad1 signaling pathways.
How do specific mutations affect the binding affinity of RNA-binding domains?4 answersSpecific mutations can affect the binding affinity of RNA-binding domains. One approach to overcome the low affinity of RNA-binding domains is to use conservative mutations that enhance their affinity. Deep learning models have been used to predict the impact of human lineage mutations (HLM) on RNA-binding protein affinity. It was found that only a small number of HLM have a large impact on RNA-binding protein affinity, and these mutations are enriched in genes critical for cognition and bipedal walking. Regression algorithms have been developed to predict the effects of mutations on protein-DNA and protein-RNA interactions. These algorithms utilize geometric partition-based energy features and interface-based structural features to estimate binding affinity changes resulting from mutations. A study on SARS-CoV-2 identified a silent mutation in the RNA binding domain of the nucleocapsid phosphoprotein gene, which may lead to a missense mutation and increased affinity of the RNA binding domain to viral RNA. A computational method called PremPRI has been developed to predict the effects of single mutations in RNA binding proteins on protein-RNA interactions. This method utilizes sequence- and structure-based features to calculate binding affinity changes.
How do specific mutations affect the binding affinity of DNA-binding domains?4 answersSpecific mutations in DNA-binding domains can affect the binding affinity of these domains. Analysis of human homeodomains (HDs) revealed that many variants altered DNA binding affinity and/or specificity. Computational methods combining Rosetta-based optimization and molecular dynamics simulations have been developed to accurately predict the effects of long-distance mutations on protein-protein binding. Regression algorithms incorporating energy and structural features have been developed to predict the effects of mutations on protein-DNA and protein-RNA interactions. Mutations in the PAX6 gene, which encodes a DNA-binding protein, were found to affect DNA-binding affinity, but the relationship between DNA-binding affinity and phenotypic differences was not straightforward. These findings highlight the importance of studying the effects of specific mutations on DNA-binding affinity and the need for accurate prediction methods for understanding the impact of mutations on protein-protein and protein-nucleic acid interactions.
What is the prevalence of CRAF mutations in urothelial cancer?4 answersThe prevalence of CRAF mutations in urothelial cancer was not mentioned in the provided abstracts.
Are there any mutations in asthma?4 answersMutations in asthma have been studied in several papers. One study found that Familial Mediterranean Fever (FMF) mutations were less frequent in allergic rhinitis and asthma cases compared to the normal population. Another study identified common polymorphisms and rare mutations in allergy-associated susceptibility genes in a family affected by allergic asthma. TACI mutations were found to be associated with an increased risk of wheeze and asthma in children. Additionally, ORMDL genes were found to be associated with asthma, with asthmatics exhibiting increased levels of ORMDL expression. Finally, mutations in ADAM33 were analyzed and several detrimental mutations were identified, suggesting their importance in asthma treatment. These studies highlight the role of genetic mutations in asthma susceptibility and provide insights into potential mechanisms underlying the development of asthma.
What transcription factors are expected to bind in the vicinity of p53 binding site?5 answersTranscription factors that are expected to bind in the vicinity of p53 binding sites include Dmp1, E2F1, YB-1, and YY1. Dmp1 specifically binds to p53 and blocks the known functions of Mdm2 in inhibiting p53, providing an additional mechanism for tumor suppression. E2F1 and YY1 can bind to both p53 and Mdm2, while YB-1 only binds to p53. These interactions with p53 and Mdm2 have different consequences for tumor development and suppression. Additionally, p53 has been shown to directly bind to the histone H3-H4 complex via its N-terminal region, suggesting a direct interaction with nucleosomes. Furthermore, p53 binding is influenced by the chromatin accessibility of a cell line, with different cell lines showing variability in gene expression despite a large overlap in p53 bound loci.